BP-C1 in Metastatic Breast Cancer Patients

Summary

This study is an open label, non-randomized phase I single-armed study in women with metastatic breast cancer (MBC) who have previously undergone all available standard chemotherapy regimens. The purpose of the study is to estimate the pharmacokinetics (PK) after single dose and multiple dose of BP-C1, investigate interleukin levels during BP-C1 treatment and assess treatment response according to RECIST criteria.

Timeline

Start

2014-01-19

Primary completion

2016-01-20

Completion

2016-01-20

Drugs

Indications